CPSE:ZEALBiotechs
Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Positive Petrelintide Phase 2 Obesity Trial Results
Why Zealand Pharma stock is in focus after new obesity trial data
Zealand Pharma (CPSE:ZEAL) has moved into the spotlight after announcing that its investigational obesity therapy petrelintide met the primary endpoint in a large Phase 2 trial, showing statistically significant weight loss versus placebo.
See our latest analysis for Zealand Pharma.
The positive petrelintide data arrives after a difficult period for Zealand Pharma shareholders. A 30 day share price return of 29.15% and a 90 day...